Syeda Fadak Zahra Hujjat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Syeda Fadak Zahra Hujjat has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Saad Khan
Jinnah Sindh Medical University, Karachi, Pakistan
8 shared publications - Abubakr Mahmoud
Department of Medicine, University of Khartoum, Khartoum, Sudan
7 shared publications - Harshika Khaim Chandani
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
7 shared publications - Devya Khaim Chandani
Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College (SMBBMC), Karachi, Pakistan
6 shared publications - Aminath Waafira
The Maldives National University
1 shared publication - Erum Siddiqui
Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 7 September 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (10) , 6229-6231
Jideytro (zidesamtinib) for previously treated ros1-positive non-small cell lung cancer: a new era in post-tki therapy
ROS1-positive non-small cell lung cancer (NSCLC) is a distinct oncogene-driven subtype that commonly affects younger, never-smokers and frequently develops central nervous system metastases and kinase-domain resistance mutations. Although first- and second-generation ROS1 tyrosine kinase inhibitors (TKIs) have improved outcomes, most patients eventually progress after treatment. On 22 July 2026, the U.S. Food and Drug Administration approved Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive NSCLC previously treated with a ROS1 TKI. Zidesamtinib is a selective, brain-penetrant, macrocyclic ROS1 inhibitor that spares tropomyosin receptor kinase (TRK) signaling while maintaining activity against diverse resistance mutations, including G2032R. In the pivotal ARROS-1 trial, it produced durable responses in heavily pretreated patients, including those with brain metastases, with low treatment discontinuation. Although prospective comparisons with crizotinib, entrectinib, repotrectinib, and taletrectinib are needed, zidesamtinib represents an important addition to post-TKI therapy for ROS1-positive NSCLC.
- 7 September 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (10) , 6229-6231
Open AccessJideytro (zidesamtinib) for previously treated ros1-positive non-small cell lung cancer: a new era in post-tki therapy
ROS1-positive non-small cell lung cancer (NSCLC) is a distinct oncogene-driven subtype that commonly affects younger, never-smokers and frequently develops central nervous system metastases and kinase-domain resistance mutations. Although first- and second-generation ROS1 tyrosine kinase inhibitors (TKIs) have improved outcomes, most patients eventually progress after treatment. On 22 July 2026, the U.S. Food and Drug Administration approved Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive NSCLC previously treated with a ROS1 TKI. Zidesamtinib is a selective, brain-penetrant, macrocyclic ROS1 inhibitor that spares tropomyosin receptor kinase (TRK) signaling while maintaining activity against diverse resistance mutations, including G2032R. In the pivotal ARROS-1 trial, it produced durable responses in heavily pretreated patients, including those with brain metastases, with low treatment discontinuation. Although prospective comparisons with crizotinib, entrectinib, repotrectinib, and taletrectinib are needed, zidesamtinib represents an important addition to post-TKI therapy for ROS1-positive NSCLC.
- Open Access
- 4 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 3924-3927
Garadacimab and the future of hereditary angioedema prophylaxis: a step upstream in the bradykinin pathway
Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent, potentially life-threatening episodes of bradykinin-mediated angioedema affecting the skin, gastrointestinal tract, and upper airway. Despite the availability of several prophylactic therapies, there is a need for effective and convenient treatment options. On 21 June 2024, the U.S. Food and Drug Administration approved Andembry™ (garadacimab-gxii), a first-in-class monoclonal antibody that inhibits activated Factor XII (FXIIa), for prophylaxis of HAE attacks in patients aged ≥12 years. By targeting FXIIa, garadacimab acts upstream in the kallikrein–kinin pathway, suppressing bradykinin generation and preventing vascular permeability associated with angioedema. Clinical trials demonstrated substantial reductions in attack frequency, with the phase 3 VANGUARD study reporting a 91.5% reduction in HAE attacks and that approximately 77% of patients remain attack-free during the study period. Garadacimab is administered as a 200-mg subcutaneous injection once monthly and has a favorable pharmacokinetic profile with an elimination half-life of approximately 18–20 days. Adverse events were generally mild, including headache, nasopharyngitis, and injection-site reactions. The approval of garadacimab represents an important advancement in HAE prophylaxis, offering a novel upstream mechanism, convenient dosing, and potential improvement in quality of life of the patients.
- 4 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 3924-3927
Open AccessGaradacimab and the future of hereditary angioedema prophylaxis: a step upstream in the bradykinin pathway
Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent, potentially life-threatening episodes of bradykinin-mediated angioedema affecting the skin, gastrointestinal tract, and upper airway. Despite the availability of several prophylactic therapies, there is a need for effective and convenient treatment options. On 21 June 2024, the U.S. Food and Drug Administration approved Andembry™ (garadacimab-gxii), a first-in-class monoclonal antibody that inhibits activated Factor XII (FXIIa), for prophylaxis of HAE attacks in patients aged ≥12 years. By targeting FXIIa, garadacimab acts upstream in the kallikrein–kinin pathway, suppressing bradykinin generation and preventing vascular permeability associated with angioedema. Clinical trials demonstrated substantial reductions in attack frequency, with the phase 3 VANGUARD study reporting a 91.5% reduction in HAE attacks and that approximately 77% of patients remain attack-free during the study period. Garadacimab is administered as a 200-mg subcutaneous injection once monthly and has a favorable pharmacokinetic profile with an elimination half-life of approximately 18–20 days. Adverse events were generally mild, including headache, nasopharyngitis, and injection-site reactions. The approval of garadacimab represents an important advancement in HAE prophylaxis, offering a novel upstream mechanism, convenient dosing, and potential improvement in quality of life of the patients.
- RetractedOpen Access
- 21 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3042-3044
Enflonsia (clesrovimab) and the future of RSV lower respiratory tract disease prevention in neonates
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in infants, with the highest burden in those under 6 months of age. Global RSV epidemics occur seasonally and nearly all children are infected within the age of 2 years, resulting in significant hospitalizations, morbidity, and healthcare costs. Enflonsia™ (clesrovimab-cfor), recently approved by the U.S. Food and Drug Administration, is a long-acting recombinant monoclonal antibody targeting the prefusion F protein of RSV, preventing viral entry and replication. A single intramuscular dose provides protection across the RSV season, eliminating the need for monthly injections. Clinical trials indicate that clesrovimab reduces RSV-related hospitalizations by up to 76% and medically attended RSV disease by over 70%, with a safety profile comparable to existing antibodies like palivizumab and nirsevimab. Common adverse events include mild injection-site reactions and rare hypersensitivity. While its high cost and cold-chain requirements may limit accessibility in low- and middle-income countries, the single-dose, season-long protection offers logistical advantages and potential cost-effectiveness in high-burden settings. Enflonsia represents a significant advance in infant RSV prophylaxis, with implications for global health strategies, integration into immunization programs, and equitable access to reduce RSV morbidity worldwide.
- 21 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3042-3044
RetractedOpen AccessEnflonsia (clesrovimab) and the future of RSV lower respiratory tract disease prevention in neonates
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in infants, with the highest burden in those under 6 months of age. Global RSV epidemics occur seasonally and nearly all children are infected within the age of 2 years, resulting in significant hospitalizations, morbidity, and healthcare costs. Enflonsia™ (clesrovimab-cfor), recently approved by the U.S. Food and Drug Administration, is a long-acting recombinant monoclonal antibody targeting the prefusion F protein of RSV, preventing viral entry and replication. A single intramuscular dose provides protection across the RSV season, eliminating the need for monthly injections. Clinical trials indicate that clesrovimab reduces RSV-related hospitalizations by up to 76% and medically attended RSV disease by over 70%, with a safety profile comparable to existing antibodies like palivizumab and nirsevimab. Common adverse events include mild injection-site reactions and rare hypersensitivity. While its high cost and cold-chain requirements may limit accessibility in low- and middle-income countries, the single-dose, season-long protection offers logistical advantages and potential cost-effectiveness in high-burden settings. Enflonsia represents a significant advance in infant RSV prophylaxis, with implications for global health strategies, integration into immunization programs, and equitable access to reduce RSV morbidity worldwide.
- Open Access
- 2 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 42-44
Orexin receptor 2 agonists: a pathophysiologic approach to narcolepsy type 1
Narcolepsy type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, and disturbed nocturnal sleep, resulting from the loss of hypothalamic neurons that produce orexin. Current therapies, including stimulants, antidepressants, and sodium oxybate, primarily offer symptomatic relief without addressing the underlying orexin deficiency and often have safety or adherence limitations. Orexin receptor 2 (OX2R) agonists represent a novel therapeutic strategy aimed at restoring physiological wakefulness by directly targeting the core neurochemical deficit. TAK-994, the first oral OX2R agonist, demonstrated remarkable efficacy in reducing cataplexy and improving wakefulness but was discontinued due to dose-dependent hepatotoxicity. TAK-861 (oveporexton), a next-generation OX2R agonist with improved structural properties, has shown encouraging Phase 2 results with comparable efficacy and a favorable safety profile, including minimal hepatic effects and once-daily dosing convenience. If validated in large-scale Phase 3 studies, TAK-861 could become the first disease-modifying therapy for NT1, representing a paradigm shift from symptomatic management to mechanism-based treatment. The ongoing development of OX2R agonists highlights a promising frontier in precision sleep medicine, offering renewed hope for patients by targeting orexin restoration.
- 2 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 42-44
Open AccessOrexin receptor 2 agonists: a pathophysiologic approach to narcolepsy type 1
Narcolepsy type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, and disturbed nocturnal sleep, resulting from the loss of hypothalamic neurons that produce orexin. Current therapies, including stimulants, antidepressants, and sodium oxybate, primarily offer symptomatic relief without addressing the underlying orexin deficiency and often have safety or adherence limitations. Orexin receptor 2 (OX2R) agonists represent a novel therapeutic strategy aimed at restoring physiological wakefulness by directly targeting the core neurochemical deficit. TAK-994, the first oral OX2R agonist, demonstrated remarkable efficacy in reducing cataplexy and improving wakefulness but was discontinued due to dose-dependent hepatotoxicity. TAK-861 (oveporexton), a next-generation OX2R agonist with improved structural properties, has shown encouraging Phase 2 results with comparable efficacy and a favorable safety profile, including minimal hepatic effects and once-daily dosing convenience. If validated in large-scale Phase 3 studies, TAK-861 could become the first disease-modifying therapy for NT1, representing a paradigm shift from symptomatic management to mechanism-based treatment. The ongoing development of OX2R agonists highlights a promising frontier in precision sleep medicine, offering renewed hope for patients by targeting orexin restoration.
- Open Access
- 8 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 1-4
Jascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial pneumonia with poor prognosis and limited therapeutic options. Despite the introduction of pirfenidone and nintedanib, treatment discontinuation due to adverse effects remains common, highlighting the need for better-tolerated, mechanistically distinct agents. Jascayd (nerandomilast), a first-in-class selective phosphodiesterase-4B inhibitor developed by Boehringer Ingelheim, was approved by the FDA in October 2025 for adults with IPF. By elevating intracellular cyclic adenosine monophosphate (cAMP) in inflammatory and structural lung cells, nerandomilast suppresses pro-inflammatory cytokines and fibroblast activation, producing anti-inflammatory and antifibrotic effects with improved tolerability over nonselective PDE4 inhibitors. In phase 3 FIBRONEER-IPF and FIBRONEER-ILD trials, nerandomilast significantly reduced the annual rate of forced vital capacity decline versus placebo, regardless of concomitant antifibrotic use. Common adverse effects included mild diarrhea, nausea, and fatigue, with low discontinuation rates. Long-term extension data demonstrate sustained safety and lung function preservation. Offering both monotherapy and combination potential, Jascayd establishes a new therapeutic class that targets inflammation and fibrosis concurrently, representing a pivotal advancement toward personalized, multi-pathway treatment in IPF.
- 8 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 1-4
Open AccessJascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial pneumonia with poor prognosis and limited therapeutic options. Despite the introduction of pirfenidone and nintedanib, treatment discontinuation due to adverse effects remains common, highlighting the need for better-tolerated, mechanistically distinct agents. Jascayd (nerandomilast), a first-in-class selective phosphodiesterase-4B inhibitor developed by Boehringer Ingelheim, was approved by the FDA in October 2025 for adults with IPF. By elevating intracellular cyclic adenosine monophosphate (cAMP) in inflammatory and structural lung cells, nerandomilast suppresses pro-inflammatory cytokines and fibroblast activation, producing anti-inflammatory and antifibrotic effects with improved tolerability over nonselective PDE4 inhibitors. In phase 3 FIBRONEER-IPF and FIBRONEER-ILD trials, nerandomilast significantly reduced the annual rate of forced vital capacity decline versus placebo, regardless of concomitant antifibrotic use. Common adverse effects included mild diarrhea, nausea, and fatigue, with low discontinuation rates. Long-term extension data demonstrate sustained safety and lung function preservation. Offering both monotherapy and combination potential, Jascayd establishes a new therapeutic class that targets inflammation and fibrosis concurrently, representing a pivotal advancement toward personalized, multi-pathway treatment in IPF.
- Open Access
- 28 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7903-7906
Metabolic miracle or misguided shift? Tirzepatide in the era of obstructive sleep apnea (OSA)
Obstructive sleep apnoea (OSA) is a prevalent disorder marked by recurrent upper airway obstruction during sleep, often linked to obesity and poor continuous positive airway pressure (CPAP) adherence. Tirzepatide, a dual GIP and GLP-1 receptor agonist approved for weight loss, has garnered interest as a potential pharmacologic option for OSA due to its weight-reducing effects. While early studies show modest reductions in apnoea-hypopnoea index and improved sleep quality, these benefits are indirect and fail to address the anatomical basis of OSA. Moreover, concerns about long-term efficacy, weight regain post-discontinuation, and adverse effects such as gastrointestinal symptoms and pancreatitis limit its standalone use. Tirzepatide may complement, but not replace, first-line therapies like CPAP. Future research should assess its role within integrated treatment models and clarify its impact on airway mechanics. Caution is warranted to avoid overreliance on pharmacologic solutions at the expense of established, effective interventions in managing this multifactorial condition. Further research should evaluate the integrated models that combine pharmaceutical therapy with lifestyle and mechanical therapies, investigate the direct impact on airway mechanics, and use the artificial intelligence to identify responders and optimize personalized treatment strategies.
- 28 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7903-7906
Open AccessMetabolic miracle or misguided shift? Tirzepatide in the era of obstructive sleep apnea (OSA)
Obstructive sleep apnoea (OSA) is a prevalent disorder marked by recurrent upper airway obstruction during sleep, often linked to obesity and poor continuous positive airway pressure (CPAP) adherence. Tirzepatide, a dual GIP and GLP-1 receptor agonist approved for weight loss, has garnered interest as a potential pharmacologic option for OSA due to its weight-reducing effects. While early studies show modest reductions in apnoea-hypopnoea index and improved sleep quality, these benefits are indirect and fail to address the anatomical basis of OSA. Moreover, concerns about long-term efficacy, weight regain post-discontinuation, and adverse effects such as gastrointestinal symptoms and pancreatitis limit its standalone use. Tirzepatide may complement, but not replace, first-line therapies like CPAP. Future research should assess its role within integrated treatment models and clarify its impact on airway mechanics. Caution is warranted to avoid overreliance on pharmacologic solutions at the expense of established, effective interventions in managing this multifactorial condition. Further research should evaluate the integrated models that combine pharmaceutical therapy with lifestyle and mechanical therapies, investigate the direct impact on airway mechanics, and use the artificial intelligence to identify responders and optimize personalized treatment strategies.
- Open Access
- 28 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7907-7909
Bruton’s tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by immune-mediated platelet destruction and impaired platelet production, leading to bleeding risk, morbidity, and reduced quality of life. Incomplete responses, adverse effects, and relapses are the limitations of current treatments, which include corticosteroids, intravenous immunoglobulin, rituximab, and thrombopoietin receptor agonists. On 29 August 2025, the U.S. Food and Drug Administration (FDA) approved Wayrilz (rilzabrutinib), a first-in-class oral Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with chronic or persistent ITP who have had an insufficient response to previous treatments. Through modulation of both Fc receptor and B-cell receptor signaling, the agent aims to address disease pathophysiology as a treatment that is disease-modifying in nature rather than simplistically dealing with symptoms. Clinical trials, including the key LUNA 3 trial, have shown good efficacy and safety, with durable platelet responses and minimal severe adverse events. This editorial examines rilzabrutinib’s scientific justification, clinical data, comparative analysis, side effects, financial ramifications, and potential applications in the treatment of ITP.
- 28 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7907-7909
Open AccessBruton’s tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by immune-mediated platelet destruction and impaired platelet production, leading to bleeding risk, morbidity, and reduced quality of life. Incomplete responses, adverse effects, and relapses are the limitations of current treatments, which include corticosteroids, intravenous immunoglobulin, rituximab, and thrombopoietin receptor agonists. On 29 August 2025, the U.S. Food and Drug Administration (FDA) approved Wayrilz (rilzabrutinib), a first-in-class oral Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with chronic or persistent ITP who have had an insufficient response to previous treatments. Through modulation of both Fc receptor and B-cell receptor signaling, the agent aims to address disease pathophysiology as a treatment that is disease-modifying in nature rather than simplistically dealing with symptoms. Clinical trials, including the key LUNA 3 trial, have shown good efficacy and safety, with durable platelet responses and minimal severe adverse events. This editorial examines rilzabrutinib’s scientific justification, clinical data, comparative analysis, side effects, financial ramifications, and potential applications in the treatment of ITP.
- Open Access
- 17 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 9147-9148
From dietary restriction to disease-targeted therapy: Sephience TM (sepiapterin) in phenylketonuria
Phenylketonuria (PKU) is a rare metabolic disorder caused by deficient phenylalanine hydroxylase, leading to toxic phenylalanine buildup and severe neurodevelopmental consequences if untreated. Despite advances in newborn screening and dietary management, treatment options remain limited and burdensome. The recent FDA approval of Sephience (sepiapterin) marks a major advancement in PKU care. Sepiapterin, a precursor of tetrahydrobiopterin (BH₄), enhances enzyme activity and stability, offering therapeutic benefit even in patients unresponsive to BH₄ alone. Results from the pivotal APHENITY Phase III trial demonstrated a substantial 63% mean reduction in blood phenylalanine and significant dietary liberalization, with 97% of participants able to increase natural protein intake safely. Importantly, 43% of prior non-responders to sapropterin showed clinical improvement, highlighting its potential to address key gaps in PKU management. With broad approval for children and adults, Sephience provides a disease-targeted therapy that extends beyond dietary restriction. While careful monitoring for adverse effects such as gastrointestinal symptoms and hypophenylalaninemia is required, this approval represents a transformative step in precision medicine. Sephience has the potential to redefine the standard of care and improve long-term quality of life for individuals living with PKU.
- 17 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 9147-9148
Open AccessFrom dietary restriction to disease-targeted therapy: Sephience TM (sepiapterin) in phenylketonuria
Phenylketonuria (PKU) is a rare metabolic disorder caused by deficient phenylalanine hydroxylase, leading to toxic phenylalanine buildup and severe neurodevelopmental consequences if untreated. Despite advances in newborn screening and dietary management, treatment options remain limited and burdensome. The recent FDA approval of Sephience (sepiapterin) marks a major advancement in PKU care. Sepiapterin, a precursor of tetrahydrobiopterin (BH₄), enhances enzyme activity and stability, offering therapeutic benefit even in patients unresponsive to BH₄ alone. Results from the pivotal APHENITY Phase III trial demonstrated a substantial 63% mean reduction in blood phenylalanine and significant dietary liberalization, with 97% of participants able to increase natural protein intake safely. Importantly, 43% of prior non-responders to sapropterin showed clinical improvement, highlighting its potential to address key gaps in PKU management. With broad approval for children and adults, Sephience provides a disease-targeted therapy that extends beyond dietary restriction. While careful monitoring for adverse effects such as gastrointestinal symptoms and hypophenylalaninemia is required, this approval represents a transformative step in precision medicine. Sephience has the potential to redefine the standard of care and improve long-term quality of life for individuals living with PKU.
- Open Access
- 6 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7877-7879
Harliku (nitisinone): first FDA-approved disease-modifying therapy for alkaptonuria
Alkaptonuria (AKU) is a rare autosomal recessive metabolic disorder due to a deficiency of homogentisate 1,2-dioxygenase, subsequently leading to the progressive acquisition of ochronosis, osteoarthropathy, systemic complications, and the pathological retention of homogentisic acid (HGA). Until recently, apart from supportive management which involved orthopedic surgery and symptomatic treatment, there was no attempt to slow the progress of the disease. On 19 June 2025, the U.S. Food and Drug Administration approved Harliku (nitisinone) as the first therapy to modify the progression of the disease. As a competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase, nitisinone exerts biochemical efficacy with a greater than 95% reduction of urinary excretion of HGA. The SONIA 2 and other studies funded by the NIH have demonstrated long-standing metabolic control with nitisinone, as well as improved functional outcomes and possibly cardioprotective effects. Although the evidence of long-term benefits is promising, risks of treatment, such as tyrosinemia, require attention to diet and continued monitoring. As the first single agent to be taken orally once daily, Harliku changes the paradigm of management for the rare metabolic disorder AKU from symptomatic treatment to disease-modifying therapy. It is a huge leap for other disorders of metabolism and paves the way for future innovations in therapy.
- 6 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7877-7879
Open AccessHarliku (nitisinone): first FDA-approved disease-modifying therapy for alkaptonuria
Alkaptonuria (AKU) is a rare autosomal recessive metabolic disorder due to a deficiency of homogentisate 1,2-dioxygenase, subsequently leading to the progressive acquisition of ochronosis, osteoarthropathy, systemic complications, and the pathological retention of homogentisic acid (HGA). Until recently, apart from supportive management which involved orthopedic surgery and symptomatic treatment, there was no attempt to slow the progress of the disease. On 19 June 2025, the U.S. Food and Drug Administration approved Harliku (nitisinone) as the first therapy to modify the progression of the disease. As a competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase, nitisinone exerts biochemical efficacy with a greater than 95% reduction of urinary excretion of HGA. The SONIA 2 and other studies funded by the NIH have demonstrated long-standing metabolic control with nitisinone, as well as improved functional outcomes and possibly cardioprotective effects. Although the evidence of long-term benefits is promising, risks of treatment, such as tyrosinemia, require attention to diet and continued monitoring. As the first single agent to be taken orally once daily, Harliku changes the paradigm of management for the rare metabolic disorder AKU from symptomatic treatment to disease-modifying therapy. It is a huge leap for other disorders of metabolism and paves the way for future innovations in therapy.
- Open Access
- 6 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7868-7869
Tonmya (cyclobenzaprine hydrochloride sublingual tablets): first FDA-approved therapy for fibromyalgia in over 15 years
- 6 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7868-7869
Open AccessTonmya (cyclobenzaprine hydrochloride sublingual tablets): first FDA-approved therapy for fibromyalgia in over 15 years